D
eep vein thrombosis leads to catastrophic complications of death, pulmonary embolism, and postthrombotic syndrome that are well documented in the general surgery and orthopedic surgery literature. The incidence of postoperative deep vein thrombosis in general surgery patients ranges from 16 to 30 percent, with an incidence of clinically significant pulmonary embolism of 1.6 percent 1,2 and fatal pulmonary embolism in 0.1 to 0.8 percent. 2 The incidence is even higher for orthopedic surgery patients undergoing hip or knee surgery. Without adequate thromboembolic prophylaxis, 45 to 70 percent of hip surgery patients 3 and 53 to 84 percent of knee surgery patients 4 will develop a deep vein thrombosis.
Deep vein thrombosis most commonly develops in the deep veins of the calf muscle, where there is a low incidence of clinically significant pulmonary embolism. 5 Without appropriate treatment, 20 percent of calf vein thrombi will propagate proximally, where they pose a serious threat. At least 50 percent of proximal deep vein thromboses were associated with a pulmonary embolism or recurrent deep vein thrombosis; 10 percent were immediately fatal with pulmonary embolism 5, 6 and 5 percent caused death later (as a result of right ventricular dysfunction and/or pulmonary hypertension). 5 Although the incidence of a fatal pulmonary embolism seems very low in a surgeon's personal practice, pulmonary embolism accounts for over 200,000 deaths per year in the United States alone. 3, 7, 8 Postthrombotic syndrome is a consequence of venous stasis and venous hypertension caused by damaged venous valves that no longer regulate the unidirectional flow of venous blood out of the legs and back to the heart. As a later complication of deep vein thrombosis, postthrombotic syndrome presents clinically, with the patient complaining of pain, varicose veins, and swelling of the affected lower limb, and develops in 60 to 70 percent of patients with proximal deep vein thrombosis and 16 percent of patients with calf deep vein thrombosis. 9 A total of 800,000 patients suffer annually in the United States from immediate and later complications of deep vein thrombosis. 3 Few publications in the literature report incidence rates of deep vein thrombosis and pulmonary embolism among plastic surgery patients. Reinisch et al. 10 reported a deep vein thrombosis incidence of 0.35 percent, a pulmonary embolism incidence of 0.14 percent, and a deep vein thrombosis-related death incidence of 0.001 percent from a survey of 273 surgeons performing 9937 face lifts. A recent literature search using "deep vein thrombosis" and "plastic surgery" in both OVID and Entrez PubMED databases (1966 to present) yielded only 10 English language articles that discussed deep vein thrombosis incidence or prophylaxis in plastic surgery patients. 2,10 -18 A survey was prepared that asked for specific information on the numbers of deep vein thromboses experienced by individual plastic surgeons. In addition, prophylaxis treatment data were also requested. We present an overview and summary of reported deep vein thrombosis occurrences and the respective prophylaxis and treatments used by members of the American Society of Plastic Surgeons.
MATERIALS AND METHODS
The survey consisted of eight questions on practice habits for three types of surgical procedures: face lifts, liposuction alone, and liposuction combined with abdominoplasty (Table 1) . Responders had to check a box corresponding to their answer for each procedure; only one question required the responder to write in an answer [i.e., How long is the average procedure (hr)?].
Surveys were mailed to all current members (1557) of the American Society of Plastic Surgeons.
Statistical Analysis
Survey results were tabulated in a Microsoft Excel worksheet (Microsoft Corp., Redmond, Wash.) as a logical expression (a marked answer would be entered with a value of 1 and nonselected answers would have a value of 0). Statistical analyses were performed using SPSS for Windows, release 11.5 (SPSS Inc., Chicago, Ill.). All data were analyzed by Pearson chi-square test unless otherwise stated. In all analyses, a probability value of p Ͻ 0.05 was considered significant.
RESULTS
A total of 1557 surveys were mailed to all of the current members of the American Society of Plastic Surgeons in March of 2003. Three hundred thirty-four surveys (21.4 percent response) were returned within a 2-month period. Not all queries were answered on all the surveys. Therefore, the numbers of responders are indicated in the tables and reported percentages represent the percentage of responders and not the total number of returned surveys.
Operative Experience
The number of face lifts, liposuctions, and combined procedures of abdominoplasty and liposuction (referred to from here on as combined procedure), and average reported times to complete each procedure are shown ( Table 2 ). The majority of responders perform 20 or fewer face lifts per year at an average operating time of 4 hours per operation per procedure. More than 50 liposuctions per year are performed by 35 percent of the responders, with approximately 40 percent completing between 11 and 30 procedures. The group average for liposuctions was 2.25 hours' operative time, with a range of 1.5 to 3 hours. Thirty-one percent (31 percent) of responders perform 0 to 10 combined procedures per year and 46.4 percent complete 11 to 30 procedures per year, with an average operative time of nearly 3½ hours. The average time it took for different groups of responders to perform surgery did not change by the numbers of each procedure performed per year. No statistical significance was observed in operating time among all surgeons who perform any of the procedures. Table 3 . The distributions of deep vein thrombosis/pulmonary embolism events and pulmonary embolism-associated mortalities were different among the groups (p ϭ 0.001). In face-lift procedures, only 2.5 percent of responders performing face lifts reported one to three deep vein thrombosis incidents and no mortalities.
In liposuction procedures, three mortalities (1 percent) from pulmonary embolism were reported, with a 6.8 percent total deep vein thrombosis/pulmonary embolism incidence [6.4 percent reported one to three deep vein thrombosis/ pulmonary embolism episodes and one responder (0.4 percent) reported four to seven deep vein thrombosis/pulmonary embolism episodes]. One surgeon reported a pulmonary embolism-associated mortality but no deep vein thrombosis/pulmonary embolism incidents. Two of the three mortalities were from surgeons reporting one to three deep vein thrombosis events (10 percent). No deaths were reported.
The numbers of deep vein thrombosis/pulmonary embolism events and pulmonary embolism-associated mortalities were the highest in the combined procedure group. The reported mortality incidence was approximately 3 percent, with a 13 percent deep vein thrombosis/pulmonary embolism event rate (12.3 percent had one to three events and 0.7 percent had four to seven). Two surgeons (0.7 percent) reported a pulmonary embolism-associated death without reporting any deep vein thrombosis/pulmonary embolism incidents. A pulmonary embolism-associated mortality was reported by 15.8 percent of the surgeons who reported one to three deep vein thrombosis/ pulmonary embolism events and by 50 percent of the surgeons who reported four to seven deep vein thrombosis/pulmonary embolism events.
Deep Vein Thrombosis/Pulmonary Embolism Events and Mortalities by Number of Operations Performed per Year
The number of deep vein thrombosis/pulmonary embolism events for each surgical procedure type was examined as a function of the number of procedures performed per year ( Table 4) . The difference in number of deep vein thrombosis/ pulmonary embolism events relative to number- 
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10.8 (4) 11.9 (37) The total difference in the number of deep vein thrombosis/pulmonary embolism events among the three procedure types was statistically significant (p ϭ 0.001), with the combined procedure group having the most, followed by the liposuction procedure group and face lifts having the least number of events. The distribution of pulmonary embolism-associated mortality (Table 5) reflects the same distribution as deep vein thrombosis/pulmonary embolism events; however, differences were not significant among the three procedure types (p Ͼ 0.05). One additional pulmonary embolism-associated mortality in the combined group was not included in this analysis because the responder did not indicate how many combined procedures he or she performed per year.
Deep Vein Thrombosis Prophylaxis Practice
Deep vein thrombosis prophylaxis practices among the responding surgeons by number of procedures performed per year and the procedure group averages are presented in Table 6 . Combination/other refers to a deep vein thrombosis prophylaxis regimen that is nonconventional or practiced by only a few responding surgeons. Interestingly, 18.4 percent of surgeons performing face lifts, 25.2 percent of those performing liposuction, and 8.6 percent of those performing a combined procedure use no deep vein thrombosis prophylaxis in their practice.
The number of reported deep vein thrombosis/pulmonary embolism events (none, one to three, and four to seven) divided by deep vein thrombosis prophylaxis regimen was not statistically different (Table 7) . Surprisingly, for both the face lift and liposuction procedure groups, the incidence of deep vein thrombosis/pulmonary embolism was greater in the any prophylaxis group than in the no prophylaxis group (Table 8 ).
In the combined procedures group, the deep vein thrombosis/pulmonary embolism incidence was statistically significant, and the incidence of deep vein thrombosis/pulmonary embolism was lower in the any prophylaxis group.
The majority of responders for all three operations report using deep vein thrombosis prophylaxis all the time ( Table 9 ). The number of deep vein thromboses was higher among those who use deep vein thrombosis prophylaxis all the time compared with those who use it less than 10 percent of the time or inconsistently. An opinion of this finding is found in the Discussion. In addition, no statistically significant differences in the distribution of prophylaxis regimen or number of procedures performed were observed for any of the operations (see Tables A, B , and C in the online Journal at www.PRSJournal.com).
Reported Mortality
There were no reported pulmonary embolism mortalities among those surgeons who perform face lifts. In liposuction alone, the deep vein thrombosis prophylaxis methods used for the three reported mortalities from pulmonary embolism are listed in Table 10 . One responder who reported not having any deep vein thrombosis/ pulmonary embolism events did report having mortality. One death was reported among those who use stockings and sequential compression devices. For combined procedures of abdominoplasty and liposuction, deep vein thrombosis prophylaxis practices for the seven pulmonary embolism-associated deaths are listed in Table 11 . . In cases where there is an "or" (e.g., "Stockings or foot pumps") the responder selected each individually and did not select possible combination choices (such as "Stockings plus foot pumps").
Plastic and Reconstructive Surgery • January 2007 DVT, deep vein thrombosis; PE, pulmonary embolism; SCD, sequential compression device; LMWH, low-molecular weight heparin; SQ, subcutaneous. *Combinations/other represent all other DVT prophylaxis practice not already shown. Combined procedures refer to a combined abdominoplasty and liposuction procedure. †The percentage of a DVT incident for all prophylaxis methods (e.g., there was one DVT in the "Nothing" DVT prophylaxis group in the face lift surgery group; this single episode represents 12.5% of all 1-3 DVT/PE incidents in the past 5 years). ‡The percentage of DVT prophylaxis practice among all surgeons performing listed surgery [e.g., under face lifts, 60 (18.9%) of all surgeons use nothing for DVT prophylaxis, and of those 60 surgeons, one had a DVT incident, which is 0.3% of the total].
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Two surgeons reported pulmonary embolism mortality without reporting any deep vein thrombosis/pulmonary embolism events. The highest incidence of pulmonary embolism death was with those who used some combination of deep vein thrombosis prophylaxis methods (42.9 percent) followed by those using sequential compression devices alone as their deep vein thrombosis prophylaxis method (28.6 percent). No statistical significance was found with the prophylaxis regimen used and pulmonary embolism-associated mortality. Tables 12 and 13 list how responders treat a DVT during the first 24 hours and 24 to 72 hours postoperatively, respectively. Responders from all three surgery types use heparin the most for the treatment of deep vein thrombosis. The second most commonly used treatment was other; the majority of responders choosing other would consult another medical service to manage the deep vein thrombosis.
Treatment Practices
Reported deep vein thrombosis treatment was grouped by deep vein thrombosis prophylaxis (those who use any deep vein thrombosis prophylaxis) and those who used no prophylaxis (Table  14) . For all three procedure groups, a high percentage of surgeons failed to indicate both a deep vein thrombosis prophylaxis practice and a deep vein thrombosis treatment plan. The nonresponder rate was 41.3 percent (n ϭ 133) in the face lift procedure group, 42.5 percent (n ϭ 137) in the liposuction procedure group, and 40.4 percent (n ϭ 130) in the combination group. For all three procedure groups, the reported differences of deep vein thrombosis treatment practice between those who used no deep vein thrombosis prophylaxis and any deep vein thrombosis prophylaxis was statistically significant by chi-square analysis (p Ͻ 0.001).
DISCUSSION Deep Vein Thrombosis Prophylaxis
This survey has demonstrated that plastic surgeons may not be fully aware of their patients' deep vein thrombosis risk. Among those surgeons performing face lifts, 16.4 percent do not use any deep vein thrombosis prophylaxis; for those surgeons performing liposuction, 21.3 percent do not use any deep vein thrombosis prophylaxis and 8.7 percent of surgeons performing a combined abdominoplasty-liposuction procedure have decided not to use any deep vein thrombosis prophylaxis. Only 48.7 percent of surgeons performing face lifts, 43.7 percent of surgeons performing liposuction, and 60.8 percent performing a combined procedure use deep vein thrombosis prophylaxis all the time. Common to all three operations, the most common deep vein thrombosis prophylaxis practice is to use sequential compression devices alone. Some improvement has been made within the plastic surgery community. In the survey by Reinisch et al. 10 60.7 percent of the responding surgeons performing face lifts reported using no deep vein thrombosis prophylaxis. Fiftyseven percent of otolaryngologists performing head and neck surgery for cancer responded in a survey 19 that they do not use deep vein thrombosis prophylaxis.
Proper deep vein thrombosis prophylaxis unquestionably decreases the incidence of deep vein thrombosis. Sequential compression device use alone has been shown to reduce the incidence of deep vein thrombosis by 60 percent. 20 Low-molecular-weight heparin has decreased the incidence of proximal vein thrombosis (without any increase in bleeding complications) by 78 percent. 21 Subcutaneous heparin (minidose heparin or low-dose unfractionated heparin) administered twice daily reduces the incidence of deep vein thrombosis by 69 percent and fatal pulmonary embolism by 96 percent. Plastic and Reconstructive Surgery • January 2007 DVT, deep vein thrombosis; PE, pulmonary embolism; SCD, sequential compression device. *This table shows DVT prophylaxis regimens and reported DVT/PE events in the past 5 years and is further divided into two parts: DVT/PE events not associated with a DVT-associated mortality and DVT/PE events that are associated with a mortality. Combinations are any other combination of DVT prophylaxis not already shown. One mortality was reported without an associated DVT/PE incident in the "Use Nothing" DVT prophylaxis group. †The percentage a particular DVT prophylaxis regimen makes to a specific 5-year DVT/PE incidence. For example, 70 surgeons responded that they do not use any form of DVT prophylaxis and did not report any DVT/PE incidence; these 70 surgeons represent 25.8% of all DVT prophylaxis regimens that also did not report any DVT/PE incidents. However, one surgeon in the "Use Nothing" group reported one to three DVT/PE events in 5 years; that one surgeon represents 6.3% of all "1-3 DVT/PE events" (including the two in the mortality part of the table). ‡The percentage a particular DVT prophylaxis regimen within a group DVT/PE events makes to either a DVT-associated mortality or not. For example, one surgeon reported using stockings for DVT prophylaxis also had one to three DVT/PE events in 5 years and reported a DVT-associated mortality. This one incident of mortality is 33.3% of all DVT-associated deaths and 6.3% of all "1-3 DVT/PE" events (there were two reported mortalities in the "1-3 DVT/PE" group (those two incidents are 12.5% of all "1-3 DVT/PE" events).
22
Plastic and Reconstructive Surgery • January 2007 100.0 DVT, deep vein thrombosis; PE, pulmonary embolism; SCD, sequential compression device. * Table shows DVT prophylaxis regimens and reported DVT/PE events in the past 5 years and is further divided into two parts: DVT/PE events not associated with a DVT-associated mortality and DVT/PE events that are associated with a mortality. Combinations are any other combination of DVT prophylaxis not already shown. One mortality was reported without an associated DVT/PE incident in the "Use Nothing" DVT prophylaxis group. †The percentage a particular DVT prophylaxis regimen makes to a specific 5-year DVT/PE incidence. See Table 10 .
for an explanation of how to read this table. ‡The percentage a particular DVT prophylaxis regimen within a group DVT/PE events makes to either a DVT-associated mortality or not.
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It is well established that deep vein thrombosis prophylaxis will result in a lower reported deep vein thrombosis/pulmonary embolism incidence compared with no prophylaxis. [1] [2] [3] 19, 21 In this survey, the reported deep vein thrombosis incidence among surgeons using no deep vein thrombosis prophylaxis was lower for the face lift group (2.8 percent among those using prophylaxis versus 1.7 percent for those who do not) and the liposuction group (6.3 percent among those who use prophylaxis versus 2.6 percent who do not). Only the combined procedure group had an expected deep vein thrombosis incidence of 10.7 percent for those using prophylaxis versus 28 percent for those who do not. An assumption is made that among those surgeons who us prophylaxis, there is a higher awareness and surveillance for deep vein thrombosis compared with those who do not use any deep vein thrombosis prophylaxis. Table  15 shows the results of an adjusted deep vein thrombosis/pulmonary embolism incident for the no prophylaxis group based on this assumption. DVT, deep vein thrombosis; ASA, aspirin; LWMH, low-molecular-weight heparin; tPA, tissue plasminogen activator; IVC, inferior vena cava. *Distribution of treatment practices for responders who used no prophylaxis or any prophylaxis is significant (p 0.001) by Pearson chi-square analysis. Percentages represent the percent of responders using the listed treatment option for each the no prophylaxis or any prophylaxis group. Combined procedures refer to a combined abdominoplasty and liposuction procedure. One responder in the face lift group responded that he would use nothing or have an IVC filter placed. DVT, deep vein thrombosis; PE, pulmonary embolism. *Table shows the calculated expected incidence of deep vein thrombosis/pulmonary embolism events in the no prophylaxis subgroups. Calculated numbers were rounded off and are reported as whole numbers. Numbers were calculated by using the DVT/PE incidence in the any prophylaxis group (see Table 8 ) and adjusting the DVT/PE incidence in the no prophylaxis group by assuming that DVT prophylaxis will decrease the incidence of reported DVTs by 66 to 25 percent. For example, in the liposuction group, the actual reported DVT incidence in the any prophylaxis group was 14 (6.3 percent). If DVT prophylaxis decreases the incidence of DVT, the incidence of DVT should be higher in the no prophylaxis group, but in this case it was lower at a reported incidence of two (2.6 percent). If the incidence of DVT was 6.3 percent in the any prophylaxis group and this represented a decreased incidence of 66 percent, the adjusted DVT incidence in the no prophylaxis group should have been 11 (or 14.3 percent of the group). †Expected DVT incidence (n) ϭ [DVT number in the any prophylaxis group/(1 -percent change)] Ϭ Total number in the any prophylaxis group ϫ Total number in no prophylaxis group. ‡p 0.05 by chi-square analysis (calculated DVT incidence compared with actual).
The adjusted values were calculated by using the deep vein thrombosis/pulmonary embolism numbers for the any prophylaxis use group (see Table 8 ) and assume that this value represents an expected 66 percent, 50 percent, 40 percent, or 25 percent decrease from the no prophylaxis group's deep vein thrombosis/pulmonary embolism occurrences. The adjusted deep vein thrombosis/ pulmonary embolism numbers were not significantly different from the actual numbers for the face lift group.
The adjusted values for a 66 percent and 50 percent decrease of deep vein thrombosis/pulmonary embolism occurrences was found to be significant from the reported number for the liposuction group. For example, if deep vein thrombosis prophylaxis results in a 66 percent decrease in the deep vein thrombosis incidence, the expected reported deep vein thrombosis incidence without any deep vein thrombosis prophylaxis would be 14.3 percent (significantly higher than the actual reported incidence of 2.6 percent).
For the combined procedures group, the adjusted deep vein thrombosis incidence was found to be consistent with the actual reported deep vein thrombosis incidence (28 percent actual incidence versus 32 percent for a calculated adjusted value). In this group, deep vein thrombosis prophylaxis resulted in a 61.7 percent decrease in the reported deep vein thrombosis/pulmonary embolism numbers. The authors stress to the reader that these percentages are not the incidences of deep vein thrombosis for each of the listed procedures; rather, they are the percentages of responding surgeons reporting a deep vein thrombosis.
The results of this survey suggest that plastic surgeons need to incorporate a deep vein thrombosis prophylaxis regimen into their practices and to be more vigilant for the signs and symptoms of deep vein thrombosis. Part of the problem may be a paucity of literature on deep vein thrombosis and deep vein thrombosis prophylaxis for plastic surgery patients. The American College of Chest Physicians remarked in their Sixth Consensus Conference on Antithrombotic Therapy 23 that many physicians do not use thromboprophylaxis because of the belief that the overall incidence of deep vein thrombosis among hospitalized and postoperative patients has declined to a point so low that prophylaxis is no longer warranted. Another possible reason may be the concern for bleeding complications. A complete discussion of this topic is beyond the scope of this article; however, multiple studies have shown no increase in the risk of major bleeding with low-dose unfractionated heparin or low-molecular-weight heparin use. There is a slightly higher risk of minor bleeding with low-dose unfractionated heparin use compared with low-molecular-weight heparin. 24 The American Society of Plastic and Reconstructive Surgeons convened a Task Force on Deep Vein Thrombosis in 1998. Their findings and recommendations were published 2 as a detailed and elegant discussion on deep vein prophylaxis and recommendations for prophylaxis inferred from the recommendations made by the American College of Chest Physicians at the Fifth American College of Chest Physicians Consensus Conference. 25 The Task Force had to infer their recommendations because plastic surgery patients were not included in the studies that American College of Chest Physicians used to formulate their recommendations. In 2001, the Sixth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy 23 published a comprehensive discussion on deep vein thrombosis prophylaxis that stratified the risk of developing a deep vein thrombosis as low, moderate, high, and highest; within each level of risk are steps labeled A, B, and C. The levels and steps of risk are defined by the patient's age (i.e., Ͻ40, 40 to 60, or Ͼ60 years), type of surgery (i.e., minor, major, nonmajor, certain orthopedic procedures, and trauma), and additional risk factors (there is a long list of risk factors). Plastic surgery patients were not included in this Consensus Conference. The problem that remains, especially for the plastic surgeon, is how to decide what are major, nonmajor, or minor operations and then assign an arbitrary risk level. The Practice Advisory on Liposuction 15, 26 recommends the intraoperative use of intermittent compression devices and lowmolecular-weight heparin for patients at higher risk-but "higher risk" is not defined.
Kaboli et al. 27 compiled a deep vein thrombosis prophylaxis options table for specific surgical patients based on the recommendations of the American College of Chest Physicians and a comprehensive review of the literature. The recommendation includes guidance on what modalities can be used as the sole antithrombotic agent/ device and those that should be used in combination. Davison et al. 12 developed an algorithm for deep vein thrombosis prophylaxis to be used by plastic surgeons based on risk assignment. The article contains a detailed discussion on risk assignment and detailed information about the different treatment modalities.
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